Drug Search Results
More Filters [+]

Diphenhydramine

Alternative Names: diphenhydramine, benadryl, Diphenydramine, difenhidramina, diphen, hydramine, belix, silphen, dibenil, beldin, antitussive, vicks formula 44, di-phen, benylin
Latest Update: 2024-06-28
Latest Update Note: Clinical Trial Update

Product Description

Diphenhydramine is used to relieve red, irritated, itchy, watery eyes; sneezing; and runny nose caused by hay fever, allergies, or the common cold. Diphenhydramine is also used to relieve cough caused by minor throat or airway irritation.

Mechanisms of Action: H1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Diphenhydramine

Countries in Clinic: China, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Acute Urticaria|Multiple Sclerosis|Schizophrenia

Phase 1: Healthy Volunteers|Insomnia|Pain Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Ketamine in negative symptoms

P3

Active, not recruiting

Schizophrenia

2024-11-03

YYKQ-202210

P1

Not yet recruiting

Insomnia

2023-10-31

43%

SIBP-R002

P1

Completed

Unknown

2023-01-09

21%

SIBP-R002

P1

Completed

Unknown

2023-01-09

21%

PRECEPT

P3

Completed

Multiple Sclerosis

2022-05-13

Recent News Events